Oral Glyceryl Triacetate (GTA) in Newborns With Canavan
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00724802 |
Recruitment Status : Unknown
Verified June 2011 by Shaare Zedek Medical Center.
Recruitment status was: Recruiting
First Posted : July 30, 2008
Last Update Posted : June 21, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Canavan Disease | Dietary Supplement: GTA (Glyceryl triacetate) Drug: GTA glyceryl triacetate | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Oral Glyceryl Triacetate (GTA) in Newborns With Canavan |
Study Start Date : | March 2008 |
Actual Primary Completion Date : | August 2008 |

- Dietary Supplement: GTA (Glyceryl triacetate)
0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 monthsOther Name: No other names are available for this drug
- Drug: GTA glyceryl triacetate
0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
- brain MRI at the end of the study [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 18 Months (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- clinical diagnosis of Canavan disease
Exclusion Criteria:
- Age above 18 months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00724802
Contact: Gheona Alterescu, MD | 972-2-6666435 | gheona@szmc.org.il |
Israel | |
Shaare Zedek Medical Center | Recruiting |
Jerusalem, Israel, 91031 | |
Contact: Gheona Alterescu, MD 972-26666435 gheona@szmc.org.il | |
Principal Investigator: Gheona Alterescu, MD |
Principal Investigator: | Gheona Alterescu, M.D. | Shaare Zedek Medical Center |
Responsible Party: | Dr. Gheona Alteresco, Shaare Zedek Medical Center |
ClinicalTrials.gov Identifier: | NCT00724802 |
Other Study ID Numbers: |
canavangta |
First Posted: | July 30, 2008 Key Record Dates |
Last Update Posted: | June 21, 2011 |
Last Verified: | June 2011 |
babies with canavan disease |
Canavan Disease Hereditary Central Nervous System Demyelinating Diseases Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Leukoencephalopathies Demyelinating Diseases |
Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn Metabolism, Inborn Errors Metabolic Diseases Triacetin Antifungal Agents Anti-Infective Agents |